RT Journal Article SR Electronic T1 Integrative genetic and immune cell analysis of plasma proteins in healthy donors identifies novel associations involving primary immune deficiency genes JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.03.26.21254301 DO 10.1101/2021.03.26.21254301 A1 Caron, Barthelemy A1 Patin, Etienne A1 Rotival, Maxime A1 Charbit, Bruno A1 Albert, Matthew L A1 Quintana-Murci, Lluis A1 Duffy, Darragh A1 Rausell, Antonio A1 , YR 2021 UL http://medrxiv.org/content/early/2021/03/29/2021.03.26.21254301.abstract AB Blood plasma proteins play an important role in immune defense against pathogens, including cytokine signaling, the complement system and the acute-phase response. Recent large-scale studies have reported genetic (i.e. quantitative trait loci, pQTLs) and non-genetic factors, such as age and sex, as major determinants to inter-individual variability in immune response variation. However, the contribution of blood cell composition to plasma protein heterogeneity has not been fully characterized and may act as a confounding factor in association studies. Here, we evaluated plasma protein levels from 400 unrelated healthy individuals of western European ancestry, who were stratified by sex and two decades of life (20-29 and 60-69 years), from the Milieu Intérieur cohort. We quantified 297 proteins by Luminex in a clinically certified laboratory and their levels of variation were analysed together with 5.2M single-nucleotide polymorphisms. With respect to non-genetic variables, we included more than 700 lifestyle and biochemical factors, as well as counts of seven circulating immune cell populations measured by hemogram and standardized flow cytometry. Collectively, we found 152 significant associations involving 49 proteins and 20 non-genetic variables. Consistent with previous studies, age and sex showed a global, pervasive impact on plasma protein heterogeneity, while body mass index and other health status variables were among the non-genetic factors with the highest number of associations. After controlling for these covariates, we identified 100 and 12 pQTLs acting in cis and trans, respectively, collectively associated with 87 plasma proteins and including 30 novel genetic associations. Genetic factors explained the largest fraction of the variability of plasma protein levels, as compared to non-genetic factors. In addition, blood cell fractions, including leukocytes, lymphocytes and three types of polymorphonuclear cells, had a larger contribution to inter-individual variability than age and sex, and appeared as confounders of specific genetic associations. Finally, we identified new genetic associations with plasma protein levels of eight monogenic Mendelian disease genes including three primary immunodeficiency genes (Ficolin-3, Interleukine-2 Receptor alpha and FAS). Our study identified novel genetic and non-genetic factors associated to plasma protein levels which may inform health status and disease management.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT01699893 NCT03905993Funding StatementThis work benefited from support of the Invest in the Future programme from the French government. This programme is managed by the Agence Nationale de la Recherche, reference ANR-10-LABX-69-01. The Clinical Bioinformatics Laboratory of the Imagine Institute was partly supported by the French National Research Agency (ANR) Investissements d'Avenir Program (Grant ANR-10-IAHU-01).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Samples came from the Milieur Interieur Cohort, which was approved by the Comite de Protection des Personnes - Ouest 6 (Committee for the protection of persons) on June 13th, 2012 and by French Agence nationale de securite du medicament (ANSM) on June 22nd, 2012. The study is sponsored by Institut Pasteur (Pasteur ID-RCB Number: 2012-A00238-35), and was conducted as a single centre interventional study without an investigational product. The original protocol was registered under ClinicalTrials.gov (study NCT01699893). The samples and data used in this study were formally established as the Milieu Interieur biocollection (NCT03905993), with approvals by the Comite de Protection des Personnes - Sud Mediterranee and the Commission nationale de l'informatique et des libertes (CNIL) on April 11, 2018.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe SNP array data that support the findings of this study have been deposited in the European Genome-Phenome Archive (EGA) with the accession code EGAS00001002460. Further data access is provided for research use only after review and approval by the Milieur Interieur data access committee. Requests can be sent to milieuinterieurdac{at}pasteur.fr https://ega-archive.org/studies/EGAS00001002460